Journal of Pediatric Pharmacology and Therapeutics最新文献

{"title":"New Tic Disorder in a Child With Cystic Fibrosis Treated With Elexacaftor/Tezacaftor/Ivacaftor.","authors":"Stephanie R Duehlmeyer, E Claire Elson, Christopher M Oermann","doi":"10.5863/1551-6776-29.1.82","DOIUrl":"10.5863/1551-6776-29.1.82","url":null,"abstract":"<p><p>The widespread use of highly effective cystic fibrosis transmembrane-conductance regulator -modulator therapy has dramatically altered the lives of individuals with cystic fibrosis. Clinical trials leading to -modulator approval by the US Food and Drug Administration demonstrated improvements in major -outcome measures including pulmonary function, gastrointestinal symptoms, and quality of life. Subsequent clinical experience has confirmed significant improvement across these domains. Adverse effects reported -during clinical trials included headache and dizziness amongst others including upper respiratory infections, abdominal pain, diarrhea, rash, and elevated serum transaminases. Post marketing clinical experience has suggested that there may be additional central nervous system adverse effects resulting from modulator therapy. Reported events after initiation of cystic fibrosis transmembrane-conductance regulator modulator treatment include headaches and increased prevalence of mental health concerns including anxiety and depression. We report a new tic disorder in a 7-year-old girl with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"29 1","pages":"82-84"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10849685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Select Abstracts of the 32nd Annual Pediatric Pharmacy Association (PPA) Meeting","authors":"","doi":"10.5863/1551-6776-28.3.272","DOIUrl":"https://doi.org/10.5863/1551-6776-28.3.272","url":null,"abstract":"","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41812428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Omadacycline as a Component of Mycobacterium Abscessus Eradication in an Adolescent With Cystic Fibrosis.","authors":"Mary Kate Tucker,&nbsp;Lee Droemer,&nbsp;Michelle Condren","doi":"10.5863/1551-6776-28.2.172","DOIUrl":"https://doi.org/10.5863/1551-6776-28.2.172","url":null,"abstract":"<p><p>Lung damage caused by non-tuberculous mycobacteria (NTM) infections can be devastating to individuals that are predisposed to chronic respiratory colonization. Cystic fibrosis patients are at increased risk for diminished lung function and increased mortality from NTM pulmonary infections. Treatment regimens are often intense and prolonged. The case described in this report is of a 16-year-old male with cystic fibrosis infected with <i>Mycobacterium abscessus</i> who showed evidence of severe nodular pulmonary disease on chest computerized tomography. His intensive treatment phase was complicated by neutropenia and drug resistance, leading to the use of omadacycline. Because of rapid improvement clinically and on computed tomography, he was successfully treated with a modified, less intense continuation phase that included azithromycin, omadacycline, and inhaled amikacin. The patient also was switched from tezacaftor/ivacaftor to elexacaftor/tezacaftor/ivacaftor during the course of NTM treatment.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 2","pages":"172-176"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10150898/pdf/i2331-348X-28-2-172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9412543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of a Pharmacist Admission Medication Reconciliation Service at a Children's Hospital.","authors":"Sara W Hovey,&nbsp;Kristen W Click,&nbsp;Jessica L Jacobson","doi":"10.5863/1551-6776-28.1.36","DOIUrl":"https://doi.org/10.5863/1551-6776-28.1.36","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the clinical effect and estimate cost avoidance attributed to a pharmacist-led admission medication reconciliation service at a children's hospital.</p><p><strong>Methods: </strong>This was a prospective observational cohort study that measured pharmacist interventions for pediatric patients over a 90-day period. Pharmacists logged all interventions identified during medication reconciliation in real time. Patient demographic data were collected retrospectively. Cost avoidance from prevented adverse drug events (ADEs) was estimated based on previously published literature.</p><p><strong>Results: </strong>Pharmacists completed 283 admission medication reconciliations during the study period. Of those, 69% of medication reconciliations required intervention. Interventions affected care during the hospital admission in 21.9% of patients and 8 medication reconciliations resulted in prevention of a major ADE. This pharmacist-led service resulted in an estimated cost avoidance of $46,746.65 in the 3-month period.</p><p><strong>Conclusions: </strong>Implementation of a pharmacist-led admission medication reconciliation service for pediatric patients improved medication safety and resulted in significant cost avoidance, which justifies investment in these pharmacist resources.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 1","pages":"36-40"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901323/pdf/i2331-348X-28-1-36.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10697524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of Parenteral Potassium Supplementation in Pediatric Patients.","authors":"Amanda A Clouser,&nbsp;Cristian D Merchan,&nbsp;Ferras Bashqoy,&nbsp;Joanna L Tracy,&nbsp;John Papadopoulos,&nbsp;Anasemon Saad","doi":"10.5863/1551-6776-28.1.48","DOIUrl":"https://doi.org/10.5863/1551-6776-28.1.48","url":null,"abstract":"<p><strong>Objective: </strong>The primary objective was to evaluate the effect of parenteral potassium chloride (KCl) supplementation on potassium (K⁺) concentrations in a non-cardiac pediatric population. Secondary outcomes were to identify variables that may influence response to KCl supplementation (i.e., change in K⁺ concentration after KCl administration) and assess the incidence of hyperkalemia.</p><p><strong>Methods: </strong>This single-center, retrospective study evaluated infants and children who received parenteral KCl supplementation of 0.5 or 1 mEq/kg between January 2017 and December 2019.</p><p><strong>Results: </strong>The study included 102 patients with a median age of 1 year (IQR, 0.4-3.9) and weight of 9.1 kg (IQR, 4.9-14.2) who received 288 parenteral KCl administrations. One hundred seventy-three administrations were in the 1 mEq/kg group, and 115 administrations were in the 0.5 mEq/kg group. The median changes in K⁺ were 0.8 and 0.5 mEq/L in the 1 mEq/kg and 0.5 mEq/kg groups, respectively. Patients who had a repeat K⁺ concentration within 4 hours of the end of a 1 to 2-hour infusion had a higher median change in K⁺ compared with those who had a concentration drawn after this time frame (0.8 vs 0.6 mEq/L; p < 0.01).</p><p><strong>Conclusions: </strong>There is a paucity of data on the correlation between parenteral KCl supplementation and change in K⁺ concentrations in pediatric patients. Our study demonstrated an association between KCl supplementation doses of 1 and 0.5 mEq/kg and changes in K⁺ of 0.8 and 0.5 mEq/L, respectively, in non-cardiac pediatric patients, with low observed incidence of hyperkalemia.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 1","pages":"48-54"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901324/pdf/i2331-348X-28-1-48.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10697525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Congenital Cytomegalovirus and Ganciclovir Therapeutic Drug Monitoring in Twin Preterm Infants.","authors":"Pierre-Philippe Piché-Renaud,&nbsp;Charles-Olivier Chiasson,&nbsp;Julie Autmizguine,&nbsp;Philippe Ovetchkine,&nbsp;Christian Lachance,&nbsp;Yves Théorêt,&nbsp;Brigitte Martin","doi":"10.5863/1551-6776-28.1.93","DOIUrl":"https://doi.org/10.5863/1551-6776-28.1.93","url":null,"abstract":"<p><p>Congenitally acquired cytomegalovirus (CMV) infection is the most prevalent congenital infection worldwide and the most frequent cause of acquired sensorineural hearing loss. The burden of the disease is even more important in premature and very low birth weight infants. However, few data exist on the treatment with intravenous ganciclovir and oral valganciclovir in this vulnerable population. We report the case of twins congenitally infected with CMV and born prematurely at 27 weeks' gestation. Treatment regimens were initially individualized for their prematurity and renal function, and then adjusted with therapeutic drug monitoring (TDM) to adapt to their continuously evolving physiologic maturation. As infants were aging, the plasmatic half-life of ganciclovir slowly decreased to term infant values around 10 weeks of chronological age, or 37 weeks of postmenstrual age. Results for blood polymerase chain reaction tests became negative and long-term follow-ups were satisfactory in both twins. The limited data for infants born before 32 weeks of gestation or at less than 1200 g and evolution of ganciclovir pharmacokinetic parameters justify the use of TDM in these settings.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 1","pages":"93-101"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9901313/pdf/i2331-348X-28-1-93.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10704614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Antiemetics in the Management of Pediatric Cannabinoid Hyperemesis Syndrome.","authors":"Emily Geraci,&nbsp;Carrie Cake,&nbsp;Kevin M Mulieri,&nbsp;Norman E Fenn","doi":"10.5863/1551-6776-28.3.222","DOIUrl":"https://doi.org/10.5863/1551-6776-28.3.222","url":null,"abstract":"<p><strong>Objective: </strong>As a result of recent legislative changes allowing for increased access to marijuana products, there have been increasing rates of cannabis abuse among adolescents and subsequent diagnoses of cannabinoid hyperemesis syndrome (CHS). Most available literature on this syndrome exists within the adult population and describes benzodiazepines, haloperidol, and topical capsaicin as potentially efficacious in the management of CHS. The objectives of this study were to identify antiemetics and compare their efficacy and safety in the management of pediatric CHS.</p><p><strong>Methods: </strong>A retrospective review of Penn State Children's Hospital electronic health record was performed to identify patients 18 years or younger who had an emergency department or inpatient encounter, a cannabis hyperemesis-related diagnosis code, and met diagnostic criteria for CHS. Antiemetic efficacy was determined using subjective patient perception of nausea and objective documentation of vomiting. Benzodiazepines, haloperidol, and topical capsaicin were classified as nontraditional antiemetics, whereas all other antiemetics were classified as traditional.</p><p><strong>Results: </strong>Nontraditional antiemetic medications appeared to be more effective in resolving patient symptoms compared with traditional antiemetics. Analysis of all ordered antiemetics demonstrated a gap in partial or full symptom resolution between nontraditional and traditional agents. Reported adverse effects were minimal.</p><p><strong>Conclusions: </strong>Cannabinoid hyperemesis syndrome is an underrecognized and underdiagnosed condition characterized by cyclic vomiting related to chronic cannabis use. Abstinence from cannabis remains the most effective approach to mitigating morbidity associated with CHS. Medications such as lorazepam or droperidol may have benefit in managing toxidrome symptoms. Traditional antiemetic prescribing remains a key barrier to effective management of pediatric CHS.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 3","pages":"222-227"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249977/pdf/i2331-348X-28-3-222.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9611220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence-AI-and The Journal of Pediatric Pharmacology and Therapeutics.","authors":"Michael D Reed","doi":"10.5863/1551-6776-28.4.284","DOIUrl":"10.5863/1551-6776-28.4.284","url":null,"abstract":"","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 4","pages":"284-286"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547040/pdf/i2331-348X-28-4-284.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Systematic Review and Meta-analysis of Rituximab-Associated Infections Among Children and Adolescents With Glomerular Disease: Focus on the Risk of Infections.","authors":"Zhara Pouransiri,&nbsp;Farahnak Assadi,&nbsp;Masoumeh Mohkam,&nbsp;Nakysa Hooman,&nbsp;Zahra Rostami,&nbsp;Mojgan Mazaheri,&nbsp;Anoush Azarfar,&nbsp;Fatemeh Ghane Sharbaf","doi":"10.5863/1551-6776-28.4.308","DOIUrl":"https://doi.org/10.5863/1551-6776-28.4.308","url":null,"abstract":"<p><strong>Objective: </strong>This systematic review and meta-analysis aimed to explore rituximab (RTX) associated infectious complications in children with glomerular disease.</p><p><strong>Methods: </strong>We performed an electronic search of PubMed, International Scientific Information (ISI), Scopus, and EMBASE between January 2010 and July 2021. Infection rates and total drug-related adverse events were the outcomes. Statistical heterogeneity was evaluated by using the <i>I²</i> statistic. When there was statistical evidence of heterogeneity (<i>I</i>² > 50%, p > 0.1), a random-effect model was adopted. Data analysis was performed with Stata17.0 software.</p><p><strong>Results: </strong>A total of 7 studies with 668 patients (136 with lupus nephritis [LN] and 532 with nephrotic syndrome were included in the meta-analysis. The pooled risk ratio showed that the administration of RTX was significantly associated with lower risk of infectious complications in patients with LN and nephrotic syndrome (0.72 [95% CI 0.58, 0.85]) when compared with population data of patients without glomerular disease (p = 0.2). There was no significant difference between the LN and nephrotic syndrome groups in terms of total serious adverse events or the occurrence of infections. There was significant heterogeneity among the reported studies (Q = 42.39, p < 0.001, <i>I</i>² = 81%).</p><p><strong>Conclusion: </strong>Administration of RTX in children with glomerular disease is associated with a lower rate of infections when compared with population data of patients without LN or nephrotic syndrome. Additional high-quality randomized controlled trials with long-term follow-up are needed to identify the long-term potential complications. Trial registration PROPERO ID: CRD42021274869 (https://www.crd.york.ac/prospero/display_record.php?).</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 4","pages":"308-315"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547046/pdf/i2331-348X-28-4-308.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41111954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal Inference in Traumatic Brain Injury: A Case of Head Trauma and Mismatched Symptoms.","authors":"Alexandra Fife,&nbsp;Kendra Larsen","doi":"10.5863/1551-6776-28.4.365","DOIUrl":"10.5863/1551-6776-28.4.365","url":null,"abstract":"<p><p>We present a case of a 14-month-old female presenting to the emergency department with head trauma. When her symptoms deviated from those associated with typical head trauma, the emergency department pharmacy team recognized a vital clue that directed the medical team toward the actual mechanism of injury and appropriate treatment of the child.</p>","PeriodicalId":37484,"journal":{"name":"Journal of Pediatric Pharmacology and Therapeutics","volume":"28 4","pages":"365-367"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10547044/pdf/i2331-348X-28-4-365.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41132413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}